EA044101B1 - Циклоолефиновые замещённые гетероароматические соединения и их применение - Google Patents
Циклоолефиновые замещённые гетероароматические соединения и их применение Download PDFInfo
- Publication number
- EA044101B1 EA044101B1 EA202090653 EA044101B1 EA 044101 B1 EA044101 B1 EA 044101B1 EA 202090653 EA202090653 EA 202090653 EA 044101 B1 EA044101 B1 EA 044101B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- formula
- independently selected
- nmr
- mhz
- Prior art date
Links
- 150000001925 cycloalkenes Chemical group 0.000 title description 2
- 150000002390 heteroarenes Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 500
- 239000000203 mixture Substances 0.000 claims description 123
- 150000003839 salts Chemical class 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 229910052717 sulfur Inorganic materials 0.000 claims description 59
- 125000005842 heteroatom Chemical group 0.000 claims description 58
- 229910052760 oxygen Inorganic materials 0.000 claims description 58
- 125000005843 halogen group Chemical group 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 230000035772 mutation Effects 0.000 claims description 29
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims description 28
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 18
- 229910052805 deuterium Inorganic materials 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 11
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 239000012488 sample solution Substances 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 5
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 2
- 208000030758 lung non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 239000012086 standard solution Substances 0.000 claims description 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 101150011812 AADAC gene Proteins 0.000 claims 1
- 101150051159 ARTN gene Proteins 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 101000958771 Homo sapiens N-acylethanolamine-hydrolyzing acid amidase Proteins 0.000 claims 1
- 102100038360 N-acylethanolamine-hydrolyzing acid amidase Human genes 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 description 286
- 239000000543 intermediate Substances 0.000 description 103
- 239000000460 chlorine Substances 0.000 description 89
- 238000000034 method Methods 0.000 description 77
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 72
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 239000003153 chemical reaction reagent Substances 0.000 description 57
- 239000000243 solution Substances 0.000 description 54
- 238000010828 elution Methods 0.000 description 50
- 238000003818 flash chromatography Methods 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 39
- 239000007787 solid Substances 0.000 description 39
- -1 hydrocarbon radical Chemical class 0.000 description 35
- 239000012071 phase Substances 0.000 description 35
- 229910001868 water Inorganic materials 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 32
- 150000002367 halogens Chemical group 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 25
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 229940125904 compound 1 Drugs 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 229920006395 saturated elastomer Polymers 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 239000012299 nitrogen atmosphere Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 210000001853 liver microsome Anatomy 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 125000006413 ring segment Chemical group 0.000 description 10
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 9
- 229940127007 Compound 39 Drugs 0.000 description 9
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- QREOHOYPZAAYPF-RXMQYKEDSA-N 3-[4-amino-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2-fluorocyclohex-2-en-1-one Chemical compound NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(CCC1)=O)F QREOHOYPZAAYPF-RXMQYKEDSA-N 0.000 description 7
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 7
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 7
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 7
- 238000007259 addition reaction Methods 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000004296 chiral HPLC Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000012363 selectfluor Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- YHRBZNGMDPUUKR-UWTATZPHSA-N 4,6-dichloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazin-2-amine Chemical compound ClC1=NC(=NC(=N1)Cl)N[C@@H](C(F)(F)F)C YHRBZNGMDPUUKR-UWTATZPHSA-N 0.000 description 5
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 5
- KLELHOXQISRKMJ-UHFFFAOYSA-N FC(F)(F)c1cc(Nc2nc(Cl)nc(Cl)n2)ccn1 Chemical compound FC(F)(F)c1cc(Nc2nc(Cl)nc(Cl)n2)ccn1 KLELHOXQISRKMJ-UHFFFAOYSA-N 0.000 description 5
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 5
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 5
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- PSUYOKDBQPJIGD-RXMQYKEDSA-N 2,6,6-trifluoro-3-[4-(methoxyamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-one Chemical compound FC=1C(C(CCC=1C1=NC(=NC(=N1)NOC)N[C@@H](C(F)(F)F)C)(F)F)=O PSUYOKDBQPJIGD-RXMQYKEDSA-N 0.000 description 4
- WSTAJOSUPLLONL-SSDOTTSWSA-N 2,6,6-trifluoro-3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-one Chemical compound FC=1C(C(CCC=1C1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C)(F)F)=O WSTAJOSUPLLONL-SSDOTTSWSA-N 0.000 description 4
- CITSYXNOEJEMEG-SNVBAGLBSA-N 2-fluoro-3-[4-(4-methoxyanilino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-one Chemical compound FC=1C(CCCC=1C1=NC(=NC(=N1)NC1=CC=C(C=C1)OC)N[C@@H](C(F)(F)F)C)=O CITSYXNOEJEMEG-SNVBAGLBSA-N 0.000 description 4
- RYXMVZLINIMQLX-LLVKDONJSA-N 2-fluoro-3-[4-[(4-methoxyphenyl)methylamino]-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-one Chemical compound FC=1C(CCCC=1C1=NC(=NC(=N1)NCC1=CC=C(C=C1)OC)N[C@@H](C(F)(F)F)C)=O RYXMVZLINIMQLX-LLVKDONJSA-N 0.000 description 4
- YQFCKOVKRFVTAQ-UHFFFAOYSA-N 2-fluoro-3-hydroxycyclohex-2-en-1-one Chemical compound OC1=C(F)C(=O)CCC1 YQFCKOVKRFVTAQ-UHFFFAOYSA-N 0.000 description 4
- GNWFJOVCKLOJPW-UHFFFAOYSA-N 3-[4,6-bis[[tert-butyl(dimethyl)silyl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-one Chemical compound [Si](C)(C)(C(C)(C)C)NC1=NC(=NC(=N1)N[Si](C)(C)C(C)(C)C)C1=C(C(C(CC1)(F)F)=O)F GNWFJOVCKLOJPW-UHFFFAOYSA-N 0.000 description 4
- DNFVDSUYBQYXSE-SSDOTTSWSA-N 3-[4-(cyclopropylmethylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-one Chemical compound C1(CC1)CNC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)(F)F)=O)F DNFVDSUYBQYXSE-SSDOTTSWSA-N 0.000 description 4
- MGHAQVKFDXOOPT-SECBINFHSA-N 3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-3-en-1-one Chemical compound C(C)(C)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C=1CC(CCC=1)=O MGHAQVKFDXOOPT-SECBINFHSA-N 0.000 description 4
- INKYQBWMDBJEIG-VJSCVCEBSA-N 3-[4-[(3,3-difluorocyclobutyl)amino]-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6-difluorocyclohex-2-en-1-one Chemical compound FC1(CC(C1)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)F)=O)F)F INKYQBWMDBJEIG-VJSCVCEBSA-N 0.000 description 4
- WCYXJRRHGAOTEF-SCSAIBSYSA-N 3-[4-chloro-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-one Chemical compound ClC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)(F)F)=O)F WCYXJRRHGAOTEF-SCSAIBSYSA-N 0.000 description 4
- XQHLMOTWSZLDBU-GFCCVEGCSA-N 6-[3-[tert-butyl(dimethyl)silyl]oxy-2-fluorocyclohexa-1,3-dien-1-yl]-4-N-(3,3-difluorocyclobutyl)-2-N-[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound [Si](C)(C)(C(C)(C)C)OC=1C(=C(CCC=1)C1=NC(=NC(=N1)NC1CC(C1)(F)F)N[C@@H](C(F)(F)F)C)F XQHLMOTWSZLDBU-GFCCVEGCSA-N 0.000 description 4
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 235000019489 Almond oil Nutrition 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- CZLYWFIYNPCCCN-UHFFFAOYSA-N C(C)(C)(C)ONC1=NC(=NC(=N1)Cl)Cl Chemical compound C(C)(C)(C)ONC1=NC(=NC(=N1)Cl)Cl CZLYWFIYNPCCCN-UHFFFAOYSA-N 0.000 description 4
- HQLVVZIKYJIHER-UHFFFAOYSA-N COC=1C=C(CNC2=NC(=NC(=N2)NCC2=CC(=CC(=C2)OC)OC)C2=C(C(CCC2)=O)F)C=C(C=1)OC Chemical compound COC=1C=C(CNC2=NC(=NC(=N2)NCC2=CC(=CC(=C2)OC)OC)C2=C(C(CCC2)=O)F)C=C(C=1)OC HQLVVZIKYJIHER-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- ASNWEHPUHHGXAH-UHFFFAOYSA-N FC1(CC(C1)NC1=NC(=NC(=N1)NC(C)C)C1=C(C(C(CC1)F)=O)F)F Chemical compound FC1(CC(C1)NC1=NC(=NC(=N1)NC(C)C)C1=C(C(C(CC1)F)=O)F)F ASNWEHPUHHGXAH-UHFFFAOYSA-N 0.000 description 4
- CWTHDTPJWFDQAG-UHFFFAOYSA-N FC1(CC(C1)NC1=NC(=NC(=N1)NC(C)C)C1=C(C(CCC1)=O)F)F Chemical compound FC1(CC(C1)NC1=NC(=NC(=N1)NC(C)C)C1=C(C(CCC1)=O)F)F CWTHDTPJWFDQAG-UHFFFAOYSA-N 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- ZMDDLYDPAZIZSC-UHFFFAOYSA-N NC1=NC(=NC(=N1)N)C1=C(C(C(CC1)(F)F)=O)F Chemical compound NC1=NC(=NC(=N1)N)C1=C(C(C(CC1)(F)F)=O)F ZMDDLYDPAZIZSC-UHFFFAOYSA-N 0.000 description 4
- WBWJORHKYPSMNS-UHFFFAOYSA-N NC1=NC(=NC(=N1)N)C1=C(C(CCC1)=O)F Chemical compound NC1=NC(=NC(=N1)N)C1=C(C(CCC1)=O)F WBWJORHKYPSMNS-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 4
- 239000008168 almond oil Substances 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 102200116484 rs121913502 Human genes 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VLVCERQEOKPRTG-HSHFZTNMSA-N (2r)-1,1,1-trifluoropropan-2-amine;hydrochloride Chemical compound Cl.C[C@@H](N)C(F)(F)F VLVCERQEOKPRTG-HSHFZTNMSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- WCJQCTJBTQZRRH-YOXFSPIKSA-N 2,6-difluoro-3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-one Chemical compound FC=1C(C(CCC=1C1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C)F)=O WCJQCTJBTQZRRH-YOXFSPIKSA-N 0.000 description 3
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 3
- ZRDJFTMUSSVAQV-LLVKDONJSA-N 6-(1,4-dioxaspiro[4.5]dec-7-en-7-yl)-4-N-propan-2-yl-2-N-[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound C(C)(C)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C=1CC2(OCCO2)CCC=1 ZRDJFTMUSSVAQV-LLVKDONJSA-N 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 102100039250 Essential MCU regulator, mitochondrial Human genes 0.000 description 3
- BKZFAWVOYUFIOX-UHFFFAOYSA-N FC1(CC(C1)NC1=NC(=NC(=N1)NC(C)C)C1=C(C(C(CC1)(F)F)=O)F)F Chemical compound FC1(CC(C1)NC1=NC(=NC(=N1)NC(C)C)C1=C(C(C(CC1)(F)F)=O)F)F BKZFAWVOYUFIOX-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000813097 Homo sapiens Essential MCU regulator, mitochondrial Proteins 0.000 description 3
- 101150104906 Idh2 gene Proteins 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 208000009527 Refractory anemia Diseases 0.000 description 3
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 3
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102200069690 rs121913500 Human genes 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZYVHMULTEAKKMV-UHFFFAOYSA-N (2-fluoro-3-oxocyclohexen-1-yl) trifluoromethanesulfonate Chemical compound FC1=C(CCCC1=O)OS(=O)(=O)C(F)(F)F ZYVHMULTEAKKMV-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- SHIQQFRHMPZTDD-RUQIKYNFSA-N 2,6,6-trifluoro-3-[4-(methoxyamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-ol Chemical compound FC=1C(C(CCC=1C1=NC(=NC(=N1)NOC)N[C@@H](C(F)(F)F)C)(F)F)O SHIQQFRHMPZTDD-RUQIKYNFSA-N 0.000 description 2
- CEZNAFJCTAYAPR-DUWLDVDNSA-N 2,6-difluoro-3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-ol Chemical compound FC=1C(C(CCC=1C1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C)F)O CEZNAFJCTAYAPR-DUWLDVDNSA-N 0.000 description 2
- HDZKBJFSOSEMGY-HNHGDDPOSA-N 2-fluoro-3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-ol Chemical compound FC=1C(CCCC=1C1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C)O HDZKBJFSOSEMGY-HNHGDDPOSA-N 0.000 description 2
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- GJCRNJHSLCCMQP-UHFFFAOYSA-N 3-(4,6-diamino-1,3,5-triazin-2-yl)-2,6,6-trifluorocyclohex-2-en-1-ol Chemical compound NC1=NC(=NC(=N1)N)C1=C(C(C(CC1)(F)F)O)F GJCRNJHSLCCMQP-UHFFFAOYSA-N 0.000 description 2
- SPKKDGAJVAQAPD-DKSCNQEISA-N 3-[4-(cyclopropylmethylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-ol Chemical compound C1(CC1)CNC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)(F)F)O)F SPKKDGAJVAQAPD-DKSCNQEISA-N 0.000 description 2
- JEIKSXLTZYHUSV-BFHBGLAWSA-N 3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-3-en-1-ol Chemical compound C(C)(C)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C=1CC(CCC=1)O JEIKSXLTZYHUSV-BFHBGLAWSA-N 0.000 description 2
- CFMQSJNLHDDRMT-ZMMDDIOLSA-N 3-[4-[(3,3-difluorocyclobutyl)amino]-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-ol Chemical compound FC1(CC(C1)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)(F)F)O)F)F CFMQSJNLHDDRMT-ZMMDDIOLSA-N 0.000 description 2
- ZVJNVQUEIIAGBP-ZCFIWIBFSA-N 3-[4-[(3,3-difluorocyclobutyl)amino]-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-one Chemical compound FC1(CC(C1)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)(F)F)=O)F)F ZVJNVQUEIIAGBP-ZCFIWIBFSA-N 0.000 description 2
- RABZWRKHMBACRZ-AWGJQOPUSA-N 3-[4-amino-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-ol Chemical compound NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)(F)F)O)F RABZWRKHMBACRZ-AWGJQOPUSA-N 0.000 description 2
- FEMNKBNWJVJVFK-SZBHIRRCSA-N 3-[5-fluoro-2,6-bis[[(2R)-1,1,1-trifluoropropan-2-yl]amino]pyrimidin-4-yl]cyclohex-2-en-1-ol Chemical compound FC=1C(=NC(=NC=1N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C)C1=CC(CCC1)O FEMNKBNWJVJVFK-SZBHIRRCSA-N 0.000 description 2
- LFBBGWKAOXZAFY-HTQZYQBOSA-N 3-[5-fluoro-2,6-bis[[(2R)-1,1,1-trifluoropropan-2-yl]amino]pyrimidin-4-yl]cyclohex-2-en-1-one Chemical compound FC=1C(=NC(=NC=1N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C)C1=CC(CCC1)=O LFBBGWKAOXZAFY-HTQZYQBOSA-N 0.000 description 2
- POYSISRSGJIDQZ-SZBHIRRCSA-N 3-[5-fluoro-4,6-bis[[(2R)-1,1,1-trifluoropropan-2-yl]amino]pyrimidin-2-yl]cyclohex-2-en-1-ol Chemical compound FC=1C(=NC(=NC=1N[C@@H](C(F)(F)F)C)C1=CC(CCC1)O)N[C@@H](C(F)(F)F)C POYSISRSGJIDQZ-SZBHIRRCSA-N 0.000 description 2
- KZDMYYSDEQQMLL-HTQZYQBOSA-N 3-[5-fluoro-4,6-bis[[(2R)-1,1,1-trifluoropropan-2-yl]amino]pyrimidin-2-yl]cyclohex-2-en-1-one Chemical compound FC=1C(=NC(=NC=1N[C@@H](C(F)(F)F)C)C1=CC(CCC1)=O)N[C@@H](C(F)(F)F)C KZDMYYSDEQQMLL-HTQZYQBOSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- HRLQVDHPSFEYEO-SNVBAGLBSA-N 6-(cyclohexen-1-yl)-4-N-propan-2-yl-2-N-[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound C1(=CCCCC1)C1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C HRLQVDHPSFEYEO-SNVBAGLBSA-N 0.000 description 2
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
- LUGIWJQEFNADHF-NWOXSKRJSA-N 6-chloro-2-N-(1,1,1,2,3,3,3-heptadeuteriopropan-2-yl)-4-N-[2-(trifluoromethyl)pyridin-4-yl]-1,3,5-triazine-2,4-diamine Chemical compound ClC1=NC(=NC(=N1)NC(C([2H])([2H])[2H])(C([2H])([2H])[2H])[2H])NC1=CC(=NC=C1)C(F)(F)F LUGIWJQEFNADHF-NWOXSKRJSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CPYZUNHCILBYAB-UHFFFAOYSA-N C(C)(C)(C)ONC1=NC(=NC(=N1)Cl)NC=1C=C(C#N)C=CN=1 Chemical compound C(C)(C)(C)ONC1=NC(=NC(=N1)Cl)NC=1C=C(C#N)C=CN=1 CPYZUNHCILBYAB-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102100025481 D-2-hydroxyglutarate dehydrogenase, mitochondrial Human genes 0.000 description 2
- 108030005026 D-2-hydroxyglutarate dehydrogenases Proteins 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- 239000012625 DNA intercalator Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- LWLSVNFEVKJDBZ-UHFFFAOYSA-N N-[4-(trifluoromethoxy)phenyl]-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide Chemical compound FC(OC1=CC=C(C=C1)NC(=O)N1CCC(CC1)CC1=CC(=CC=C1)OC1=NC=C(C=C1)C(F)(F)F)(F)F LWLSVNFEVKJDBZ-UHFFFAOYSA-N 0.000 description 2
- 101150003085 Pdcl gene Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- PQANGXXSEABURG-UHFFFAOYSA-N cyclohex-2-en-1-ol Chemical compound OC1CCCC=C1 PQANGXXSEABURG-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 description 2
- 229950010133 enasidenib Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 101150046722 idh1 gene Proteins 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 2
- FNYGWXSATBUBER-UHFFFAOYSA-N n-cyclohexyl-2-(3-fluoro-n-[2-(2-methylimidazol-1-yl)acetyl]anilino)-2-(2-methylphenyl)acetamide Chemical compound CC1=NC=CN1CC(=O)N(C=1C=C(F)C=CC=1)C(C=1C(=CC=CC=1)C)C(=O)NC1CCCCC1 FNYGWXSATBUBER-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000711 polarimetry Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012354 sodium borodeuteride Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ISYORFGKSZLPNW-NDCOIKGTSA-N 1,1,1,2,3,3,3-heptadeuteriopropan-2-amine;hydrochloride Chemical compound Cl.[2H]C([2H])([2H])C([2H])(N)C([2H])([2H])[2H] ISYORFGKSZLPNW-NDCOIKGTSA-N 0.000 description 1
- CCAWRGNYALGPQH-UHFFFAOYSA-N 1-[5-(cyclopropylsulfamoyl)-2-thiophen-3-ylphenyl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound FC(F)(F)C1=CC=CC(NC(=O)NC=2C(=CC=C(C=2)S(=O)(=O)NC2CC2)C2=CSC=C2)=C1 CCAWRGNYALGPQH-UHFFFAOYSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- XXBZSPPWTVRISV-UHFFFAOYSA-N 2,4,6-trichloro-5-fluoropyrimidine Chemical compound FC1=C(Cl)N=C(Cl)N=C1Cl XXBZSPPWTVRISV-UHFFFAOYSA-N 0.000 description 1
- VSPQIMBDWGTHPD-PVSHWOEXSA-N 2,6,6-trifluoro-3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-ol Chemical compound FC=1C(C(CCC=1C1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C)(F)F)O VSPQIMBDWGTHPD-PVSHWOEXSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- LYNBZRJTRHTSKI-UHFFFAOYSA-N 2-(trifluoromethyl)pyridin-4-amine Chemical compound NC1=CC=NC(C(F)(F)F)=C1 LYNBZRJTRHTSKI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 1
- GEEAYLFEIFJFGP-UHFFFAOYSA-N 2-aminopyridine-4-carbonitrile Chemical compound NC1=CC(C#N)=CC=N1 GEEAYLFEIFJFGP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- COFLACRNCXTAGM-QWWZWVQMSA-N 2-chloro-5-fluoro-4-N,6-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]pyrimidine-4,6-diamine Chemical compound ClC1=NC(=C(C(=N1)N[C@@H](C(F)(F)F)C)F)N[C@@H](C(F)(F)F)C COFLACRNCXTAGM-QWWZWVQMSA-N 0.000 description 1
- XMMAKUCGMOIOMC-IQQIRFCMSA-N 2-fluoro-3-[4-[[(1R)-1-phenylethyl]amino]-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-ol Chemical compound FC=1C(CCCC=1C1=NC(=NC(=N1)N[C@H](C)C1=CC=CC=C1)N[C@@H](C(F)(F)F)C)O XMMAKUCGMOIOMC-IQQIRFCMSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CECMHVJGNAFHKN-RAJUTSIHSA-N 3-[4,6-bis[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6,6-trifluorocyclohex-2-en-1-ol Chemical compound FC([C@@H](C)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)(F)F)O)F)(F)F CECMHVJGNAFHKN-RAJUTSIHSA-N 0.000 description 1
- WSBFRFJCBNRJBE-LPBDRPKESA-N 3-[4,6-bis[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2,6-difluorocyclohex-2-en-1-one Chemical compound FC([C@@H](C)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(C(CC1)F)=O)F)(F)F WSBFRFJCBNRJBE-LPBDRPKESA-N 0.000 description 1
- KMIARXLJAFSARV-BFHBGLAWSA-N 3-[4-(propan-2-ylamino)-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]cyclohex-2-en-1-ol Chemical compound C(C)(C)NC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=CC(CCC1)O KMIARXLJAFSARV-BFHBGLAWSA-N 0.000 description 1
- VLKHQHNWHXZHJT-FOUAAFFMSA-N 3-[4-chloro-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2-fluorocyclohex-2-en-1-ol Chemical compound ClC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)C1=C(C(CCC1)O)F VLKHQHNWHXZHJT-FOUAAFFMSA-N 0.000 description 1
- JPNPRWMRUCIEMN-UHFFFAOYSA-N 3-ditert-butylphosphaniumylpropane-1-sulfonate Chemical compound CC(C)(C)P(C(C)(C)C)CCCS(O)(=O)=O JPNPRWMRUCIEMN-UHFFFAOYSA-N 0.000 description 1
- MCLXKFUCPVGZEN-UHFFFAOYSA-N 4,6-dichloro-1,3,5-triazin-2-amine Chemical compound NC1=NC(Cl)=NC(Cl)=N1 MCLXKFUCPVGZEN-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- PILNELKJQKCJJB-SECBINFHSA-N 6-(3,3-difluorocyclohexen-1-yl)-4-N-propan-2-yl-2-N-[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound FC1(C=C(CCC1)C1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C)F PILNELKJQKCJJB-SECBINFHSA-N 0.000 description 1
- SNFPJTATKKNUOP-RUZZIDMASA-N 6-(3-methoxycyclohexen-1-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound COC1C=C(CCC1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C SNFPJTATKKNUOP-RUZZIDMASA-N 0.000 description 1
- JIAASUWPBZFIJH-RKDXNWHRSA-N 6-(cyclohexen-1-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound C1(=CCCCC1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C JIAASUWPBZFIJH-RKDXNWHRSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- DJBGNWJMUQNIOW-UVTZGIPTSA-N 6-[3-(dimethylamino)cyclohexen-1-yl]-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound CN(C1C=C(CCC1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C)C DJBGNWJMUQNIOW-UVTZGIPTSA-N 0.000 description 1
- WCJVATSGROGYCP-QWWZWVQMSA-N 6-chloro-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound ClC1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C WCJVATSGROGYCP-QWWZWVQMSA-N 0.000 description 1
- HEGCNDKBDVZEST-RXMQYKEDSA-N 6-chloro-4-N-propan-2-yl-2-N-[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine Chemical compound ClC1=NC(=NC(=N1)NC(C)C)N[C@@H](C(F)(F)F)C HEGCNDKBDVZEST-RXMQYKEDSA-N 0.000 description 1
- JFNSKKABDDUFMS-QWWZWVQMSA-N 6-chloro-5-fluoro-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]pyrimidine-2,4-diamine Chemical compound ClC1=C(C(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C)F JFNSKKABDDUFMS-QWWZWVQMSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
- 101100125460 Arabidopsis thaliana IDH3 gene Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DOISXUZMFJZDKT-UHFFFAOYSA-N C(C(C)C)(=O)NC1=NC(=NC(=N1)Cl)Cl Chemical compound C(C(C)C)(=O)NC1=NC(=NC(=N1)Cl)Cl DOISXUZMFJZDKT-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100059600 Caenorhabditis elegans cec-1 gene Proteins 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Substances [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000035131 DNA demethylation Effects 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- KTPVLWCQJPAJJV-UHFFFAOYSA-N FC1(CC(C1)NC1=NC(=NC(=N1)NC1CC(C1)(F)F)C1=C(C(CCCC1)O)F)F Chemical compound FC1(CC(C1)NC1=NC(=NC(=N1)NC1CC(C1)(F)F)C1=C(C(CCCC1)O)F)F KTPVLWCQJPAJJV-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 101000941448 Lasioglossum laticeps Lasioglossin-2 Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XDIPNUQTZCSIMD-RXMQYKEDSA-N N-[4-chloro-6-[[(2R)-1,1,1-trifluoropropan-2-yl]amino]-1,3,5-triazin-2-yl]-2-methylpropanamide Chemical compound C(C(C)C)(=O)NC1=NC(=NC(=N1)Cl)N[C@@H](C(F)(F)F)C XDIPNUQTZCSIMD-RXMQYKEDSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101150078171 OSH3 gene Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000043123 TET family Human genes 0.000 description 1
- 108091084976 TET family Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- DEVHXDJLQMAWLM-UHFFFAOYSA-N bicyclo[3.1.1]hept-3-ene Chemical compound C1C2CC1CC=C2 DEVHXDJLQMAWLM-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 1
- XZWQKJXJNKYMAP-UHFFFAOYSA-N cyclohexen-1-ylboronic acid Chemical compound OB(O)C1=CCCCC1 XZWQKJXJNKYMAP-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010001780 lipoamidase Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- ZBDXGNXNXXPKJI-UHFFFAOYSA-N o-tert-butylhydroxylamine;hydrochloride Chemical compound Cl.CC(C)(C)ON ZBDXGNXNXXPKJI-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N trifluoromethanesulfonic anhydride Substances FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Substances COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N tris(dibenzylideneacetone)dipalladium(0) Substances [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Claims (27)
- 3. РасчётРастворимость исследуемого соединения в буферах фосфата натрия рН 2,1 и рН 7,4 рассчитывали посредством следующих формул:Растворимость образца при рН 2,1 (мг/мл) = 2xAxY<XРастворимость образца при рН 7,4 (мг/мл) = 2xAxZ^X при этом:А: Концентрация исследуемого соединения в стандартном растворе образца, мг/мл;X: Площадь пика образца в стандартном растворе;Y: Площадь пика рН 2,1 в растворе образца;Z: Площадь пика рН 7,4 в растворе образца.Растворимости некоторых соединений согласно настоящему изобретению, выбранных в качестве примеров, приведены ниже:Соединение Растворимость, мг/мл Соединение Растворимость, мг/мл pH 2,1 pH 7,4 pH 2,1 pH 7,43 >1,000 0,716 125 0,448 0,0199 >1,000 0,085 219 0,190 0,06020 0,570 0,062 223 0,060 0,01668 0,141 <0,005 243 0,055 <0,00571 0,064 0,055 249 0,036 0,01182 0,146 0,037 262 0,237 0,01397 0,077 0,021 271 0,974 0,124102 0,729 <0,005 284 0,789 0,818ФОРМУЛА ИЗОБРЕТЕНИЯ1. Соединение формулы (I) ^^/NR3R3'Τ Τ nr4r4' ^pR2)m (I) и/или его фармацевтически приемлемая соль, и/или его сольваты, рацемические смеси, энантиомеры, диастереомеры и таутомеры, при этомА выбран изпри этом R7 выбран из Н, гало, -CN, -ОН или -NH2;R1 выбран из Н, -ОН, гало, О1-6алкила, C1-6алкоксила, -NH2, -NH(C1-4алкила), -N(C1-4алкила)2, оксо или C3-8циклоалкила;каждый из R2 независимо выбран из Н, дейтерия, гало, -ОН, -NH2, -CN, -SH, C1-6алкила, C2-6алкенила, О2-6алкинила, C1-6галогеналкила, C3-8циклоалкила, оксо, -OR5, -OCOR5, -NHR5, -N(R5)(C1-4алкила), -COR5, -NHCOR5 или 3-8-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S; в котором каждый из указанных C1-6алкила, С2-6алкенила, C2-6алкинила, C3-8циклоалкила или 3-8-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, необязательно содержит в качестве заместителей одну или более групп, выбранных из дейтерия, гало, -CN, -ОН, -SH, -NH2, -NH(C1-4алкила), -N(C1-4алкила)2 или C1-6алкоксила; или два R2, которые присоединены к одному и тому же атому углерода, вместе с указанным атомом углерода, к которому они присоединены, образуют 3-5-членный циклоалкил, который необязательно содержит в качестве заместителей один или более гало или дейтерий;R3' и R4', оба, являются Н; a R3 и R4 независимо выбраны из Н, C1-6алкила, C2-6алкенила, C2-6алкинила, C3-12циклоалкила, 3-12-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила, 5-12-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, -C(O)R5, -OR5 или -NHR5, в котором каждый из указанных C1-6алкила, C2-6алкенила, C2-6алкинила C3-12циклоалкила, 3-12-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила или 5-12-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, необязательно содержит в качестве заместителей один или более R6; при условии, что R3 и R4 одновременно не являются Н; при условии, что когда один из R3 и R4 представляет собой, необязательно, замещённый фе- 73 044101 нил или, необязательно, замещённый 5-6 членный гетероарил, содержащий один или более гетероатомов, независимо выбранных из N, О и S, другой представляет собой -OR5 или -NHR5; илиR3 и R3' независимо выбраны из Н, C1.6алкила, C2.6алкенила, C2.6алкинила, C3.12циклоалкила, 3-12членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила, 5-12-членного гетероарила, -C(O)R5, -OR5 или -NHR5, в котором каждый из указанных C1.6αлкила, C2.6алкенила, C2.6алкинила C3.12циклоалкила, 3-12-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила или 5-12-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, необязательно содержит в качестве заместителей один или более R6; a R4 и R4 вместе с атомом N, к которому они присоединены, образуют 3-8-членное гетероциклическое кольцо, содержащее один или более гетероатомов, независимо выбранных из N, О и S, необязательно, замещённое одним или более R6;R5 выбран из C1.6αлкила или C3.8циклоалкила, каждый из которых необязательно содержит в качестве заместителей одну или более групп, независимо выбранных из гало, -CN, -ОН, -SH, -NH2 или С1-6алкоксила;каждый из R6 независимо выбран из дейтерия, гало, -CN, -ОН, -SH, -NH2, C1.6αлкоксила, C1.6αлкила, C1.6галогеналкила, C3.8циклоалкила, 3-8-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила или 5-6-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, в котором каждый из указанных C1.6αлкоксила, C1.6алкила, C3.8циклоалкила, 3-8 членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, или 5-6-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, необязательно содержит в качестве заместителей одну или более групп, независимо выбранных из гало, -CN, -ОН, -SH, -NH2, C1.6алкоксила, C1.6αлкинила или C1.6алкила;m равно 0, 1, 2, 3, 4, 5 или 6;n равно 0, 1 или 2.
- 2. Соединение формулы (I) по п.1 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что R1 выбран из Н, -ОН или гало.
- 3. Соединение формулы (I) по п.2 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что R1 представляет собой -ОН.
- 4. Соединение формулы (I) по п.1 или его фармацевтически приемлемые соли, и/или его рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что каждый из R2 независимо выбран из Н, дейтерия, гало, -ОН, -NH2, -CN, -SH, C1.6αлкила, C2.6αлкенила, C2.6алкинила, C1.6галогеналкила, C3.8циклоалкила, оксо, -OR5, -OCOR5, -NHR5, -N(R5)(C1.4алкила), -NHCOR5 или 3-8членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S.
- 5. Соединение формулы (I) по п.4 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что каждый из R2 независимо выбран из Н, дейтерия, гало, C1.6алкила или C1.6галогеналкила.
- 6. Соединение формулы (I) по п.1 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что R3 и R4 независимо выбраны из C1.6алкила, C3.12циклоалкила, 3-12-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила, 5-12-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, -C(O)R5, -OR5 или -NHR5, в котором каждый из указанных C1.6αлкила, C3.12циклоалкила, 3-12-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенил или 5-12-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, необязательно содержит в качестве заместителей один или более R6.
- 7. Соединение формулы (I) по п.6 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что R3 и R4 независимо выбраны из C1.6алкила, замещённого одним или более гало, 5-12-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, замещённого C1.6галогеналкилом или -OR5.
- 8. Соединение формулы (I) по п.1 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что R3 и R4 независимо выбраны из C1.6алкила, замещённого одним или более гало.
- 9. Соединение формулы (I) по п.1 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что R5 представляет собой C1.6алкил, необязательно, замещённый одним или более гало.
- 10. Соединение формулы (I) по п.1 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что каждый из R6 независимо выбран из дейтерия, гало, -CN, -ОН, -NH2, C1.6алкоксила, C1.6алкила, C1.6галогеналкила,- 74 044101C3.8циклоалкила, 3-8-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила или 5-6-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, в котором каждый из указанных C1.6алкоксила, C1.6алкила, C3.8циклоалкила, 3-8-членного гетероциклила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, фенила или 5-6-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, необязательно содержит в качестве заместителей один или более гало.
- 11. Соединение формулы (I) по п. 1 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что n равно 1.
- 12. Соединение формулы (I) по п.1 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что R3 выбран из Н, C1.6алкила, необязательно, замещённого C1.6галогеналкилом, или 5-12-членного гетероарила, содержащего один или более гетероатомов, независимо выбранных из N, О и S, необязательно, замещённого C1.6галогеналкилом; R3' представляет собой Н; R4 и R4' вместе с атомом N, к которому они присоединены, образуют 3-8-членный гетероциклический цикл, содержащий один или более гетероатомов, независимо выбранных из N, О и S, необязательно замещённый одной или более группой, выбранной из гало, -ОН или C1.6галогеналкила.
- 13. Соединение формулы (I) по любому из пп.1-12 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что указанное соединение формулы (I) выбрано изпри этом X представляет собой галоген.
- 14. Соединение формулы (I) по любому из пп.1-12 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что указанное соединение формулы (I) имеет структуру формулы (II);при этом X представляет собой галоген;р равно 0, 1 или 2;m равно 0, 1 или 2;
- 15. Соединение формулы (I) по п.14 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что указанное соединение формулы (I) выбрано из- 75 044101при этом X представляет собой галоген;р равно 0, 1 или 2;m равно 0, 1 или 2.
- 16. Соединение формулы (I) по п.15 или его фармацевтически приемлемые соли, и/или его сольваты, рацемическая смесь, энантиомеры, диастереомеры и таутомеры, отличающееся тем, что указанное соединение формулы (I) имеет структуру формулы (II-1);при этом X представляет собой галоген;р равно 0, 1 или 2;m равно 0, 1 или 2;
- 17. Соединение, выбранное изСоединение Структура Соединение Структура1 GT 1F CF3 Ν ^Ν ι Η Η 152 G/OH [ iRSjT CF3 N% = A. A <R) Ν Ν Ν η2 Gr0H ΤF QF3 гАА CF3 A?n Эм 153 Αυοη Г (RSH ΑΓν ν ν3 pr0H A CF3 N^ N r-\ 7 A A A/0 An n νΆ Η Η 154 Γ (RS)| QF3 Ν^Ν ΑΓνΆ^νΆ^ Η π4 A, CF3 N^N /~AF 155 Αυοη Γ fRsjl CF3 Ν^Ν ι ΑΓν'^ν^ν'^ Η Η5 Agoh φζ cA fa\ a A Ja f Ν Ν N H H 156 ^•ιΟ ΙΖ “Η >=ζνΛΛ ΙΖ Ο G 1- 76 0441016 xyoh Л Fp АЛ А хО 157 IZ ω iz -П о A- 1 w7 Χγ0Η Л Гу X? н н 158 A CF3 N^N = AAXA An ν ΝΑπ H Η V8 гХ0Н I F CF3 N^N А к χ I N N'SYt η η V 159 A IF Г. CF3 N^N 7 A A A Ar An n n·^ H H9 ж CF3 nA I XX A X Άν ν ν'^ H H 160 Oyoh aF F CF3 N^n A?/ F AAA AJ7 An n n' H H10 A0H TF CF3 N^N r-X А А A Az O/n n H H 161 CF3 N^N rA~/° A A A X A/n n n H HИ rX0H л F CF3 N^ N CF3 A A A A An n nA H H 162 rX°H rF Г A A X H H12 A CF3 N^N A A A / An ν νΆ η η 1 163 ^OH TF CF3 N^ N = A A A A / An n n'wt η h |13 rX0H TF CF3 N^ N A A A An ν νΑί r H H ΑχΡ F 164 rXOH TF CF3 N^ N -. A A X A / O/n n na?A^ H H- 77 04410114 А°н TF CF3 N ^N CF3 165 Α0Η TF CF3 Ν^Ν Η Η15 <yoh Г (RsT г 166 a; CF3 νΆ у-Л Λ Λ A Αν ν νΆΑ Η Η (/ F16 zaoh Г А CF3 nA a ΑΛΑ An Ν nA 'F Η Η 167 ΑΟΗ ?F CF3 νΆ ι Α Α Α Λ / Αν ν νΑΚ Η Η ι17 Ήυοη Γ (RsY ул CF3 nA 1 ΛΑ A X Αν ν Η Η 168 Α<0Η a CF3 ΝΆ АК1АмАк1 A_.cn Αν ν ν (rs/^ Η Η18 TF QF3 Ν CF3 ΑΑνΛΆ 169 ΑΟΗ aF CF3 NS fF АЛ А Λ An ν nA'19 IZ -П О о -Π 170 aF CF3 N^N /F А Λ A A An n nA· H H20 Θζ0Η Λ Αν F Λ Λ X/ F Η Η 171 AOH A cf3 n A f 4AW H H \A21 θ-ΟΚ а ГЛ X3 Αν ν nA 172 A CF3 N^N ΑΝ^Ν^Ν'θΆ Η Η- 78 04410122 0$ V, N^N A FA\AAAf Ν Ν N H H 173 A CF3 N^N r-N A A A A> -^N N NtA H H23 CF3 N^N ί H H 174 A CF3 N^N ί A A A X f -X'N'^N^NiXy'24 Θ$ CF3 An rJ 4nA>n^f H H 175 A CF3 ΝΆ ί A A A X / <rTn Ν Ν^ξ< H H F F25 ί fRSl 1 N l 1 ΑΑΑΛ H H 176 cr ?F3 H'S rXxF ί Ji А A^'n^'n'^n'^7 F H H26 г A Ou- Z— Л O7g 177 a0H CF3 N^N r^\ F аааач H H27 L A N^N л f>C x л Λ H H 178 A3 A A Z/° ^N-^N^N-^ H H28 ^ОИ L iRS;l Aa5a H H 179 cr Тал C° -^N N N'’(RT H H29 Г R% QF3 |A CD3 H D C°3 180 cr CF3 N^N r^\ A A A A /° An ν ΝΎξΑ H H- 79 04410130 Γ cf3 nA cd3 WX H HD3 181 Λ. CF3 Ν^Ν TM-F АЛЛ X Λ Αννν^/ Η Η31 Θζ CF3 nA Λ A A XTF ΑΓν Ν N' H H 182 σ0Η X Η<\™ CF3 Ν^Ν ТЛ л л л X/ 'ΧΝ Ν NW4' Η Η32 ec H H 183 σ0Η CF3 nA * ΛΑ Λ Λ ο Ν Η Η33 <^0H cf3 nA ϊ H H 184 /χ,ΟΗ CF3 nA Α μ X, Α Κ1 Μ°η ^(R) Ν Ν Ν Η Η34 0 IZ Ηλά УМ IZ -no b 1 % 186 X, ΑΓν^ν^νΆ-35 θζ ?F1H л ΑΓν'Ά'Ά'Α Η Η 187 ?. γΑν^νΧα? V η η V36 CF3 Ν^Ν ϊ АЛ А X ΑΓν ν ν^ Η Η 188 9 CF3 Ν^Ν ΛΑ 1 Λ ζ An n nV,, , Η Η |όη37 6rF XVA Η Η 189 9 CF3 Ν^Ν ϊ ΑΓν^ν^νΧΗ Η- 80 04410138 F Ash 5F'll i Ά ν 190 9 CF3 N^N ϊ A A A A XrTN N N ^ H H39 Qc,° A A X H H 191 A A A A A γΑν N N'CTY? V η η V40 iz 71 ZZ “П ' д 1 τι 192 9 CF3 νΆ A A A WN Ν ΝΆ7 H H V41 or CF3 N^N <F ΆΓν'^ν<^ν'χ^'ι= H H 193 2 γ/ΆΛ' V η h42 A Х3Д А „А , ΧΑ N nIrs) V H H 194 .9 V H H43 ОГ А А г F LA AAA Ν N nAA H H 195 .944 A CQ А А X3 ν^^ν^ν^νΆ H H 196 rA0H 1 F CF3 N ^N CF3 A A A A ArTn n nIA H H45 ar XXX a a X H H 197 и 198 Λ CF3 N^N CF3 A9nXaXi9rA H H- 81 04410146 Д Η Η д Ж А3 -^Ν Ν Η Η47 ar ΝΑ nA C|O<AnAnA Η Η Д 199 ar \д 1 А л N Жон48 α: ^νΆ νΆ I Η Η 200 I шТ ШалЛ н н49 ar А Π X l A/v Η Η 201 и 202 & Ху n^n /А н н50 S^F F Д д Ху κΑν гА fXana> н н51 χ: А и д АЛАА Η Η 203 Sr Ху n^n гО, н н52 Д CF3 Ν^Ν CD3 A?nAAn^CD3 204 д Ν^Αΐ Ν<ί<Ν AAAAm-aa Ν Ν Ν >< Η Η A53 ar Ж Д3 4nAan4cd3 Н HD3 205 χ№Η 1 fRSl Ν^Ν η η- 82 044101206 Г fRsJ QF3 nA cf3 Α/Ν’^^νΆ' h [L h55 ρΑτ νΆ cd3 H HD3 207 фС QF3 nA<F CF3 ^ΧιΑγ^νΆ H M56 “Π AHA IZ -no /- 1 208 Sr CF3 N^N A A A ΆνΆΑΆρ357 N^. N^N I H H 209 CF3 NX A A A N N η η V210 Sr CF3 NX A A A / -<Κ?Ν N N H H59 ar aN-nX N^N I H H 211 Sj ?F· ГI г H H60 ъ IZ Нлд >Ам IZ -no b 1 A 212 A νΛι νΆ A A A A O / ΟΡΓ^-Ά Ν Ν' 3 Η Η61 ar An n^n CiAAnaAn xOx Η H a 213 ο ъ ΙΖ >=ΗνΛΛΖ ΙΖ -π ο Ъ 1- 83 04410162 α AAA νΧ I L JL У А л 1 Ν Ν Ν'^' Η Η 214 Ν nA Αν 3 Η Η A63 X Ή Ο U- ΖΙ Μ/ζ=< ЙА/ ΖΙ Й ζ 1 215 0 ΙΖ >=ZAV ΧΖ -Π ο64 τ —( Ο U- ΖΧ Μ/ζ=< У/ ΖΙ .Й ζ 216 X 9^ Ο u- ΖΧ %Ηη ΖΙ α ο65 8 ΙΖ >=ζ ΛΑ ΤΖ -Π Ο __ τ 217 Ν nA nA A JL Λ А Ο CFf^^N N N' ’— 3 Η Η66 - Ν 4 ,Ν~Ν Ν^Ν 1 '—4 A A A JL νΆΆΆ-ά Η Η 218 Ή nA ν^ν α£ λ λ Ρ CFa''''^-'Ά Ν ΝΑ< Η LA67 γ ΛΑ Np η η 1 он 219 Ά л· Άν ν νΆ68 χ OU- ζχ НА ΖΙ 8 220 Ο 8 τζ υΗΑ χ^ -π Ο69 Ν CF3 A QF3 Αλ/ά Η Η 221 Λ ζχ Й ο- 84 044101222 и 223 8 ΙΖ Нм ΛΑ ΙΖ -π Ο 171 Ή νΛ| νΆ cf3AAnAA'°X Η Η Ή 8 ΙΖ Ал ΙΖ И Ο 172 ο 8 ΙΖ нНа ΙΖ -Π Ο 6 -π 224 «Γ α’ΧΛ % Ή Ν Й73 ο . t НА ZI 0 LL 225 Η CF3 NX ΛΑ Α Άν ν ν ο-^ η η V74 T*Chiral 1 F nA nx । к JI Ill F^^N N N'^ H H 226 Η CF3 Ν^Χ A A A ΧΝ Ν Ν χ η η V75 к nA νΆ «.ААДА 3 Η Η Ή 227 'Г . CF3 Ν^ Ν : L II Γρ Η Η76 ar nA I AJXnanAA Η Η 228 ?- CF3 Νχ Ν r-J А А А X/ F AkN N N H H- 85 04410177 A \ /=1 N^N 1 Ν'ν^νΛ^ν^ H H 229 prOH XF ЛЛ ΝΛΝ , \ J A A A A H H78 «Г CF3 nA A к A А/ы м ыЖ η h | 230 и hr CF3 N^N A A A Άν ν ν'^H H79 ar CF3 N^N a X X N N CF3 H H 231 gr CF3 N^N A A A / afN N N^a' H H80 ar CF3 N^N a X X An N N Xv η η V 232 Ou- ZX Жн Ш zx On81 ar CF3 N% A A A / Ά Ν N — H H 233 X CF3 N^N r\ A A A X / N82 D D P gFiA i3 •^N N N-^ H H83 D D X™ ?>α Г An N N'T' H H 235 rA°H TF v CF3 N ^N A; А Л A X? ^WN N NW784 D D A , CF3 N% г-Л WA H H 236 и 237 &OH А УХ AMAF H H- 86 04410185 A An A fΆ II j £tf H H AH A aa fAa> H H238 A0H 1 F ΑνΆγΆ H H87 D D A CF3 A QF3 Άν^ν^νΆ 239 A CF3 N^n H H89 s . t °ЛС/А ZI 4 о 240 ar CF3 N^N AfAAn^f H H90 A iWA H H 241 ar Ал n^n F \A A A /x 'Ν Ν N CF3 H H91 D D A к Λ Д. fA\ananAp H H 242 A QF3 N^N CF3 Ά/ν^ν^νΆ H H92 D D A°h A\ N^N 1 fJA^/A H H 243 A CF3 N^N A A A Λν n n^\ h AyF F- 87 04410193 а;· CF3 nA Л Л A An Ν NH2 Η 244 A А А А 1 AnanAA Η Η94 Sc CF3 nA I H H A CF3 N% । 246 и с θΉ Г Αν ν νΆ95 и 96 H H η H97 и фГ ?F31 A 1 H H c QF3 N^N CF3 ΑνΛνΑΑ H H 247 ά: CF3 Ν^Ν CF3 A A A A An n nA H H98 c QF3 lA CF3 AnAAA c CF3 N^N CF3 Αν^ν^νΙκΕ-H H 249 и H HCl А. /ОН 6c 250 'X 'OH A99 Λ QF3 N^N CF3 AnAAA H H Λ ^F3A A a3 An ν νΆ H H- 88 044101100 и 101 «Г1 1 н н 251 и 252 Λ CF3 А д AnAn^n^ H H гХон aF CF3 N^N 1 Ан А X Αν ν ν'^ Η Η A Άν^ν^ν·^^ Η Η102 и 103 X 84 ОН. ΖΙ Μ ΖΤ o..(g 253 и 254 A F CF3 N^N r~J H H^.Λ°Η α Δ λ3 Αν ν νΧ X F CF3 N^N /Ύ АЛАХ H H104 и 105 Хн Θζ V nA A ΑαΆ 255 и 256 >3 yOY zz -ПО / 1 /\ Λ°Η Γ Ή AA F Λ F nA W Η Η Ao XZ w АкЛЛ/1 о J1106 и 107 θτ Ία λ' Άν Ν Ν'ίΧ 257 и 258 CF3 N^N AnAA^ H HСА ?Ίλ λ’ Αν ν nA Η Η к CF3 N^N Λ A A /^ / An n n — H H108 и 109 ^>0Η X X Λ л FWF Η Η 259 F CF3 N^N r^J Л Л Л А/ F An N N' H H- 89 044101 н н 260 А CF3 νΆ л ААА^ н нПОи 111 CFj N А CFj 261 А Аа+А н нГf ХП? 262 и 263 ^О УоА ΙΖ -ПО л 1 -П112и ИЗ D D & ?РзП Г XrIn Ν Νκ6 A F CF3 N^N r~J у3 ii л Γγ-f Η ΗD D A <η)'Ν'^Ν'^νΆ 264 и 265 0 Гл Λ Л ΑΓναναν^ Η Η114 и 115 A H H + CF3 Ν^Ν Λ γαγΆ Η ΗD D A CF3 N% Η Η 266 267 268 269 A ?F31 А Г XW’N N NW4Иби 117 А ζζ -Π □ О А 1 Г ? F3 A CF3 <R?N Ν νΆ- 90 044101D D •л Л- Н Н X a3 An n nW4118 и 119 а; А3 ΛΑ Л н н F ? D X CF3 νΆ CF3 4ААйА х\ ,όη Hf CF3 Ν^Ν ι χχχΧ H H 270 A cf3 An X/n^nAf,120 и 121 X F CF3 nA ι—/ А Λ A AA~ f An n n H H 271 X CF3 nAn ΑΑν^ν^νΎ^Χ H H XX χ\ΛΟΗ Г Ή у1''1 CF3 N^N r-J А Л А Ay ΆΓν ν n H H 272 и 273 X wA H H122 σ CF3 N^N ι A Λ A X AA n n^ H H A , H H123 A CF3 nA ι А Л A X AAn ν n H H 274 F\ZF OH & 1 nH rX λχυχχ H H124 Aaoh Г (RsjT CF3 N^N । An^n^n^ H H 275 OU- zx /НА -VA χ ZI X о- 91 044101125 он /—URS) CF3 N^N ι H H 276 о I 9 U- ZT αΜ\ζ=< ZI Q LL o126 Av0H 1 fRsj CF3 N^N CF3 A. <A A. Gr; ν ν n р?Л 277 Sc CF3 N^N CF3 GrI'n'^n'^n'A H H127 IZ >=ζνΛΛ IZ О к “Π 278 AF0 A™ Л'А A Л G^n n nx H H128 &он CF3 nAn Gr/n^n^n'^'^ H H 279 StF 0H ?G1 % G N И129 Αγ0Η [ (RSj 9F 3 N^N д ATn^n^n^^ H H 280 T I О Ll z ш ZI OI..^130 АА^и [ fRSjl cf3 An г-л GrTn^n^n^^ H H 281 A0H CF3 N^N CF3 AT Ν N131 Ar0H [ (W CF3 n^n AnAAnAC H H |oh 282 θ^0Η CF3 N^N CF3 GrTn'^n^n'^G H H132 <V0H ψ CF3 nAN Gr? N ^N Ν H H 283 G CF3 ΝΆ CF3 J, A. <A x Gs; Ν Ν N fsG- 92 044101133 xyoh ί (wsl CF3 А Д А /х / ΧΑ Ν Η Η 284 Ν<^Ν А А η2ν ν νη2134 <α0Η Γ fRSj CF3 Ν% А Д Д /х / ΧΑ ν η η 1 285 и о г ΙΖ НхХЛ/· iz -П О135 <α0Η ί fRSjl CF3 nA А Д A ^χ Χο ν ν^· Η Η 286 о ъ ΙΖ VzXpX iz -по 1136 χυοη ί (RSjJ cf3 nA ХД АД Д 1 J Xjnnn^ Η Η 287 и о ъ IZ кЦЮЛ/· угН$Х, TZ и ώ Ϊ /О137 ^χ,ΟΗ ί (RsT CF3 Ν^Α Ο aaxv η η 1 288 о ъ ΧΖ ΙΖ' -Π α т О X138 Λ CF3 Ν^Ν ί A A A Λ ΧΑ Ν Η Η 289 и А CF3 nAn А А А ХА N nh2139 / CF3 Ν Α f-\ А А А Д /° ΧΑ ν nAA 290 А CF3 N^N А А А ХА ν nh2140 ^a'a д3 ΧΑ ν nAA Η Η 291 и 292 А' ?F11 д3 ХА ν νΑτ- 93 044101141 CF3 N'M CF3 ΑΓν'^ν^νΧ' Η Η 9“ CF3 Ν^Ν CF3 An^n^ntX142 143 144 145 146 и 147 148 и 149 Η Γ cf3 nA Cf3 Α/ν νΧ Η Η [ΧΧοη CF3 nA CF3 ΑΓν'Ά^νΆ Η Η Αυοη τ CF3 Ν^Ν ϊ Α/νΧνΧν^Χ Η Η ОН Adi CF3 νΆν . ΑΓν^ΧαΧ Η Η Θ'™ CF3 Ν^Ν ϊ AT Ν hX Ν 'Χ Η Η >VH 6 CF3 νΑΝ . ΑΓν-Χ^ΧΧ Η Η I CF3 Ν^Ν CF3 A. A '(R) Ν Ν Ν А Η Η Τ>·ΟΗ τ CF3 nA CF3 ΑΓν ν' ν'Χ Η Η 293 294 295 296 297 298 299 300 Χ CF3 nA ΧΧΧά Η Η Ή Λ0Η 1 F CF3 Ν ^Ν ΑΓΝ^Ν^Ν-θΆ Η Η Ή Xl F CF3 Ν^Ν CF3 Άν'^'ν^'ν'Χ & CF3 N^N CF3 A CF3 N^N A/n^n^n'0^ H H nA nA As. JL A A ,o. Ν N H H A CF3 N^N ΧρΧΝΑΝ^F & nA n^n Al A A oh CF3 Ν Ν ΝΛ/υπ H TcF3150и 151 V X fXX λ a XXF Ν Ν Ν Η Η 301 О U- ^-X u/vaA=< ZI 4 и FvX λ a XXf Ν Ν Ν Η Η или его фармацевтически приемлемая соль.
- 18. Фармацевтическая композиция, содержащая соединение по любому из пп.1-17 или его фармацевтически приемлемую соль и по меньшей мере один фармацевтически приемлемый наполнитель.
- 19. Применение соединения по любому из пп.1-17 или его фармацевтически приемлемой соли для изготовления лекарственного средства для лечения заболевания, вызванного мутацией изоцитратдегидрогеназы (ИДГ), у субъекта, отличающееся тем, что указанное заболевание, вызванное мутацией ИДГ- 94 044101 представляет собой рак, который выбран из солидных опухолей, нейроглиоцитомы или гематологического злокачественного рака, такого как лейкемия, лимфома или миелома.
- 20. Применение по п.19, отличающееся тем, что указанный рак выбран из лейкемии, лифмомы или миеломы.
- 21. Применение по п.19, отличающееся тем, что указанный рак выбран из острого миелоидного лейкоза (AML), острого промиелоцитарного лейкоза (APL), глиобластомы (GBM), миелодиспластического синдрома (MDS), миелопролиферативного новообразования (MPN), холангиокарциномы, хондросаркомы, гигантоклеточной опухоли, рака желудочно-кишечного тракта, меланомы, рака легких или неходжкинской лимфомы (NHL).
- 22. Применение по п.21, отличающееся тем, что указанный рак представляет собой внутрипеченочную холангиокарциному (IHCC).
- 23. Соединение формулы (IV)и его рацемическая смесь или его энантиомеры, при этом R1 представляет собой -ОН или оксо, R2 и m определены в любом из пп.1-16;n равно 1 или 2;Ra выбран из гало, -OS(O)2CF3, -В(ОН)2, -B(OC1.6алкила)2,Rb представляет собой Н или C1.6алкил.
- 24. Соединение формулы (IV) по п.23, отличающееся тем, что указанное соединение формулы (IV) имеет структуру формулы (IV-1), при этом m равно 0, 1 или 2,Ч?п Г (R24 (IV-1)
- 25. Соединение формулы (IV) по п.23, отличающееся тем, имеет структуру формулы (IV-2), при этом X - гало;m равно 0, 1 или 2, г п Г (R2)-I х Ra (IV-2)
- 26. Соединение формулы (IV) по п.23, отличающееся тем, имеет структуру формулы (IV-3), при этом X - гало;р равно 0, 1 или 2;m равно 0, 1 или 2,
- 27. Соединение формулы (IV) по п.23, отличающееся тем, выбрано из что указанное соединение формулы (IV) что указанное соединение формулы (IV) указанное соединение формулы (IV) что-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710801364.3 | 2017-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA044101B1 true EA044101B1 (ru) | 2023-07-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6387360B2 (ja) | 変異idhの阻害薬としての3−ピリミジン−4−イル−オキサゾリジン−2−オン | |
JP2022546520A (ja) | Rip1阻害化合物ならびにそれを作製および使用するための方法 | |
EP3571192B1 (en) | Jak1 selective inhibitors | |
KR20230049584A (ko) | 아미노산 화합물을 사용한 호흡기 질환의 치료 | |
JP7273030B6 (ja) | シクロオレフィン置換複素芳香族化合物およびそれらの使用 | |
WO2014147586A1 (en) | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh | |
JP2022550353A (ja) | アザキノリン化合物およびその使用 | |
TW202220998A (zh) | 雜芳基雜環化合物及其用途 | |
WO2024020084A1 (en) | Heteroaryl compounds as ligand directed degraders of irak4 | |
WO2018066718A1 (en) | Therapeutic compounds | |
CN118201896A (zh) | PI3K-α抑制剂和其使用方法 | |
EA044101B1 (ru) | Циклоолефиновые замещённые гетероароматические соединения и их применение | |
EP3686197B1 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
TW202110801A (zh) | 新型醯胺類化合物及其用途 | |
NZ762447B2 (en) | Cycloolefin substituted heteroaromatic compounds and their use | |
NZ620037B2 (en) | Tricyclic heterocyclic compounds and jak inhibitors |